Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-002870
Filing Date
2025-01-07
Accepted
2025-01-07 16:30:09
Documents
3
Period of Report
2025-01-01

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1570
2 EX-24.1 ubx-ex24_1.htm EX-24.1 763
3 GRAPHIC img246442652_0.jpg GRAPHIC 889602
  Complete submission text file 0000950170-25-002870.txt   1228908
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Issuer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O APELLIS PHARMACEUTICALS, INC. 6400 WESTWIND WAY, SUITE A CRESTWOOD KY 40014
Business Address
Grossi Federico (Reporting) CIK: 0001720634 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38470 | Film No.: 25515215